Literature DB >> 17962370

Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.

T Furukawa1, M Kishiro, K Akimoto, S Nagata, T Shimizu, Y Yamashiro.   

Abstract

BACKGROUND: The use of intravenous immunoglobulin (IVIG) is well established as an initial therapy for Kawasaki disease (KD), but treatment for IVIG-resistant KD remains uncertain AIM: To analyse the effects of intravenous methylprednisolone (IVMP) pulse therapy compared with additional IVIG in IVIG-resistant patients.
METHODS: IVMP was administered to patients with KD who had persistent or recurrent fever after a single dose of IVIG, at Juntendo University Hospital and affiliated medical institutions between May 2003 and March 2006. The effectiveness of the treatment and the incidence of coronary lesions in patients who received IVMP and those who received additional IVIG were retrospectively analysed and compared by chart review.
RESULTS: 411 patients with KD were treated with a single dose of IVIG. Of the 63 IVIG-resistant patients, 44 were then given IVMP and 19 were given additional IVIG. Treatment was successful in 34 (77%) of the patients who received IVMP and 12 (63%) who received additional IVIG. Five of the 10 patients who did not respond to IVMP and two of the seven who did not respond to additional IVIG developed coronary artery aneurysms. Although fever initially resolved faster in the IVMP-resistant group, there was a delay in fever recurrence, which ultimately delayed the final resolution of fever.
CONCLUSIONS: The findings suggest that IVMP is an effective additional treatment for IVIG-resistant KD. However, there was a tendency for fever to recur later in IVMP-resistant patients, which could potentially delay the therapeutic decision-making process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962370     DOI: 10.1136/adc.2007.126144

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  25 in total

Review 1.  Pediatric vasculitis.

Authors:  Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 2.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 3.  Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

Authors:  Seyyedeh Saneeymehri; Katherine Baker; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

Review 4.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

5.  Recent advances in the understanding and management of kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

6.  Infliximab treatment for refractory kawasaki disease in korean children.

Authors:  Min Seob Song; Sang Bum Lee; Sejung Sohn; Jin Hee Oh; Kyung Lim Yoon; Ji Whan Han; Chul Ho Kim
Journal:  Korean Circ J       Date:  2010-07-26       Impact factor: 3.243

Review 7.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330

8.  Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study.

Authors:  Masayuki Teraguchi; Hirotaro Ogino; Ken Yoshimura; Shoichiro Taniuchi; Minoru Kino; Hitoshi Okazaki; Kazunari Kaneko
Journal:  Pediatr Cardiol       Date:  2012-11-27       Impact factor: 1.655

Review 9.  Epidemiology and management of Kawasaki disease.

Authors:  Nadia J C Luca; Rae S M Yeung
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

Review 10.  Medium-size-vessel vasculitis.

Authors:  Michael J Dillon; Despina Eleftheriou; Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2009-11-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.